A Study of the Safety, Tolerability and Pharmacokientics of RO5545965 in Patients With Schizophrenia on Risperidone
Status:
Completed
Trial end date:
2014-08-01
Target enrollment:
Participant gender:
Summary
This randomized, double-blinded, placebo-controlled study will investigate the safety,
tolerability, and pharmacokinetics of multiple doses of RO5545965 administered orally to
psychiatrically stable patients with schizophrenia receiving risperidone.